SILICON LABORATORIES INC. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data SILICON LABORATORIES INC. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	698	769	868	474	511	721	1,024	782	584	785
Cost of revenue	276	315	347	194	216	295	382	322	272	328
Gross profit	422	454	521	280	295	425	643	461	312	457
Research and development	200	209	238	206	235	273	332	338	332	353
Selling, general and administrative	155	160	198	163	167	185	191	147	145	174
Operating expenses	355	369	436	369	402	458	523	485	478	528
Operating income	66.3	85	85.2	-88.6	-107	-32.8	119	-24.2	-165	-70.5
Interest expense	2.59		19.7	20.2	34.1	31	6.72	5.55	1.31	0.98
Interest income	1.29
Other non-operating income	-0.49
Pre-tax income	64.5	76.9	72.2	-96	-130	-44.4	130	-26.6	-155	-57.9
Income tax	3	29.8	-11.4	6.98	-14.6	13.4	38.5	7.94	36.2	7
Net income	61.5	47.1	83.6	19.3	12.5	2,117	91.4	-34.5	-191	-64.9
EBITDA	79.5	99.7	101	-73.5	-90.8	-14.8	142	1.55	-140	-45.8
EPS, basic	1.47	1.11	1.94	0.44	0.29	49.44	2.61	-1.09	-5.93	-1.98
EPS, diluted	1.45	1.09	1.90	0.43	0.28	47.78	2.54	-1.09	-5.93	-1.98
Shares, basic (weighted)	41.7	42.4	43.2	43.3	43.8	42.8	35.1	31.8	32.2	32.7
Shares, diluted (weighted)	42.4	43.3	44	44.3	44.4	44.3	36	31.8	32.2	32.7

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	141	269	197	227	203	1,075	500	228	282	364
Short-term investments	154	495	417	499	522	965	692	212	101	79.4
Receivables	74.4	71.4	73.2	75.6	95.2	98.3	71.4	29.3	54.5	64.5
Inventory	59.6	73.1	75	73.1	47.9	49.3	100	194	106	95.6
Other current assets	21.6	21.3	64.7	30.7	35.9	38.4	97.6	75.1	59.8	70.3
Total current assets	491	948	827	944	976	2,239	1,461	738	602	674
Property, plant and equipment	130	128	139	136	136	147	152	146	132	129
Lease right-of-use assets				16.1	27.4	27.9	24.7	26.7	21.5	22.9
Goodwill	276	288	397	237	376	376	376	376	376	376
Intangible assets	104	83.1	171	134	163	119	84.9	59.5	36.5	23.1
Long-term investments	5.2
Other non-current assets	81.7	88.4	90.5	62.4	66.6	53.8	67.3	123
Total assets	1,082	1,535	1,624	1,675	1,993	2,958	2,169	1,443	1,223	1,269
Accounts payable	39.6	38.9	41.2	38.9	54.9	47.3	89.9	57.5	42.4	50.7
Accrued liabilities	50.1	33.6	37.1	41.1	46.6	42	43.7	16.9	18.6	43.5
Total current liabilities	140	162	145	138	284	669	186	164	97.9	144
Long-term debt	72.5
Lease liabilities						22.5	18	19.8	15.5	17
Other non-current liabilities	15.1	38.7	35.9		79.8	77	49.1	70.8	44.8	31.1
Total liabilities	255	582	557	560	794	746	764	234	143	175
Total debt	72.5
Paid-in capital	24.5	103	108	134	204			17	78.2	157
Retained earnings	802	851	961	981	994	2,215	1,416	1,193	1,002	937
Other comprehensive income	0.49	-1.16	-1.57	0.65	1.81	-2.42	-10.7	-1.03	0.07	0.2
Shareholders' equity	827	953	1,067	1,115	1,200	2,212	1,405	1,209	1,080	1,094
Total equity	827	953	1,067	1,115	1,200	2,212	1,405	1,209	1,080	1,094
Total liabilities and equity	1,082	1,535	1,624	1,675	1,993	2,958	2,169	1,443	1,223	1,269
Shares outstanding	41.9	42.7	43.1	43.5	43.9	38.5	32	31.9	32.5	33

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	61.5	47.1	83.6	19.3	12.5	2,117	91.4	-34.5	-191	-64.9
Depreciation and amortization	13.2	14.8	15.9	15.2	16.3	18.1	22.5	25.7	25.6	24.7
Stock-based compensation	39.6	44.8	50.1	44.3	49.5	56.8	60.5	48.2	61.5	80.3
Deferred income tax	-4.06	-26.2	-8.48	23	-6.52	16.6	-18.2	-10.9	29.5	0.88
Change in receivables	0.05	3.23	3.93	-2.4	-17.6	-3.14	26.9	42.1	-25.2	-10
Change in inventory	-6.09	-13.4	7.66	-4.2	9.15	-1.51	-51	-93.4	88.5	9.99
Change in payables	0.26	-0.47	5.95	7.83	15.3	-7.7	36.8	-25.6	-15.2	6.33
Cash from operations	129	190	174	167	136	91.2	141	-30.3	-13.9	95.7
Capital expenditures	-10.9	-12.3	-24.5	-15.3	-18.1	-28.6	-26.5	-22.3	-11.7	-29.9
Acquisitions	-6.55	-15.2	-240	-2.51	-317
Purchases of investments	-185	-636	-396	-425	-520	-1,542	-607	-103	-73.6	-34.8
Sales and maturities of investments				345	497	1,095
Cash from investing	-49.6	-374	-197	-107	-361	-477	241	470	113	-12
Debt issued					845		0	80	0	0
Debt repaid	-5	-72.5		-1.13	-625	-141	-0.02	-571	-45	0
Stock issued	13.3	11.8	13.3	14.5	15	14.2	11.8	14.6	16.3	14.6
Share buybacks	-40.5		-39.3	-26.7	-16.3	-1,150	-883	-217	-0.02	0
Cash from financing	-52.3	313	-48.8	-29.6	201	-1,299	-887	-712	-45.1	-1.07
Net change in cash	27	128	-72.3	30.1	-24.4	872	-575	-272	54.1	82.6
Free cash flow	118	177	149	151	118	62.6	115	-52.6	-25.7	65.8
Interest paid	2.22	3.86	6.23	6.37	8.66	5.01	4.43	4.47	0.99	0.63
Income taxes paid	11.2	8.93	20.6	10.3	7.22	266	132	31.7	19.1	11

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to July 4, 2026; growth uses fiscal years. Valuation uses the share price of $221.24 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	60.6%	Gross profit / revenue.
Operating margin	-5.1%	Operating income / revenue.
EBITDA margin	-2.2%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	-3.8%	Pre-tax income / revenue.
Net margin	-4.6%	Net income / revenue.
FCF margin	-0.6%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	3.9%	Cash from operations / revenue.
Return on equity (ROE)	-3.6%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	-3.1%	Net income / average total assets.
Return on invested capital (ROIC)	-4.7%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	42.2%	Research and development expense / revenue.
SG&A / revenue	23.5%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	10.2%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	4.5%	Capital expenditures / revenue.
D&A / revenue	2.8%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	34.3%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	-8.5%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	9.0%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	46.4%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	-10.7%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	9.2%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow CAGR, 3y	-12.2%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	-6.7%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Free cash flow CAGR, 3y	-16.9%	Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Free cash flow CAGR, 5y	-11.0%	Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	1.3%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	-8.0%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	-1.8%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	3.8%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-16.4%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	-8.6%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	1.6%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	-3.2%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	-5.9%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	5.41x	Current assets / current liabilities.
Quick ratio	3.84x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	3.20x	(Cash + short-term investments) / current liabilities.
Liabilities / assets	12.6%	Total liabilities / total assets.
Interest coverage	-47.0x	Operating income / interest expense.
Working capital	$547.1M	Current assets - current liabilities.
Goodwill and intangibles / assets	31.5%	(Goodwill + intangible assets) / total assets.
Tangible book value	$699.9M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.68x	Revenue / average total assets.
Fixed asset turnover	6.54x	Revenue / average property, plant and equipment.
Inventory turnover	2.73x	Cost of revenue / average inventory.
Days inventory	134 days	365 x average inventory / cost of revenue.
Receivables turnover	10.7x	Revenue / average receivables.
Days sales outstanding	34 days	365 x average receivables / revenue.
Days payables	57 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	111 days	Days inventory + days sales outstanding - days payables.
Capex / operating cash flow	116.4%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$1.18	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$25.78	Revenue / diluted weighted shares.
FCF per share	-$0.16	Free cash flow / diluted weighted shares.
Operating cash flow per share	$1.00	Cash from operations / diluted weighted shares.
Book value per share	$32.81	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$20.98	Tangible book value / shares outstanding.
Cash per share	$11.91	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$7.38B	Share price x shares outstanding.
Enterprise value	$6.98B	Market cap + total debt - cash - short-term investments.
P/S	8.62x	Market cap / revenue.
P/B	6.74x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	10.5x	Market cap / tangible book value, when positive.
P/OCF	223x	Market cap / cash from operations, when positive.
EV/Sales	8.16x	Enterprise value / revenue.
FCF yield	-0.1%	Free cash flow / market cap.
Earnings yield	-0.5%	Net income / market cap (the inverse of P/E).

What was SILICON LABORATORIES INC.'s revenue in fiscal 2025?

SILICON LABORATORIES INC. reported revenue of $784.8M for fiscal 2025, 34.3% higher than the year before.

Was SILICON LABORATORIES INC. profitable in fiscal 2025?

No. It reported a net loss of $64.9M.

How much free cash flow did SILICON LABORATORIES INC. generate in fiscal 2025?

Cash from operations of $95.7M minus capital expenditures of $29.9M left free cash flow of $65.8M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to SILICON LABORATORIES INC.